CRLBF
Price
$0.98
Change
-$0.02 (-2.00%)
Updated
Aug 15 closing price
Capitalization
341.12M
82 days until earnings call
GLASF
Price
$7.17
Change
-$0.49 (-6.40%)
Updated
Aug 15 closing price
Capitalization
615.71M
Interact to see
Advertisement

CRLBF vs GLASF

Header iconCRLBF vs GLASF Comparison
Open Charts CRLBF vs GLASFBanner chart's image
Cresco Labs
Price$0.98
Change-$0.02 (-2.00%)
Volume$2.42M
Capitalization341.12M
Glass House Brands
Price$7.17
Change-$0.49 (-6.40%)
Volume$260.07K
Capitalization615.71M
CRLBF vs GLASF Comparison Chart in %
Loading...
CRLBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GLASF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRLBF vs. GLASF commentary
Aug 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRLBF is a Hold and GLASF is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 17, 2025
Stock price -- (CRLBF: $0.98 vs. GLASF: $7.17)
Brand notoriety: CRLBF and GLASF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: CRLBF: 234% vs. GLASF: 82%
Market capitalization -- CRLBF: $341.12M vs. GLASF: $615.71M
CRLBF [@Pharmaceuticals: Generic] is valued at $341.12M. GLASF’s [@Pharmaceuticals: Generic] market capitalization is $615.71M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.74B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRLBF’s FA Score shows that 0 FA rating(s) are green whileGLASF’s FA Score has 0 green FA rating(s).

  • CRLBF’s FA Score: 0 green, 5 red.
  • GLASF’s FA Score: 0 green, 5 red.
According to our system of comparison, both CRLBF and GLASF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRLBF’s TA Score shows that 5 TA indicator(s) are bullish while GLASF’s TA Score has 5 bullish TA indicator(s).

  • CRLBF’s TA Score: 5 bullish, 4 bearish.
  • GLASF’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both CRLBF and GLASF are a good buy in the short-term.

Price Growth

CRLBF (@Pharmaceuticals: Generic) experienced а +31.61% price change this week, while GLASF (@Pharmaceuticals: Generic) price change was +13.99% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +6.26%. For the same industry, the average monthly price growth was +68.76%, and the average quarterly price growth was +80.82%.

Reported Earning Dates

CRLBF is expected to report earnings on Nov 07, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+6.26% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GLASF($616M) has a higher market cap than CRLBF($341M). GLASF YTD gains are higher at: 23.621 vs. CRLBF (7.537). CRLBF has higher annual earnings (EBITDA): 95.7M vs. GLASF (46M). CRLBF has more cash in the bank: 155M vs. GLASF (34.6M). GLASF has less debt than CRLBF: GLASF (76.1M) vs CRLBF (646M). CRLBF has higher revenues than GLASF: CRLBF (706M) vs GLASF (216M).
CRLBFGLASFCRLBF / GLASF
Capitalization341M616M55%
EBITDA95.7M46M208%
Gain YTD7.53723.62132%
P/E RatioN/A513.07-
Revenue706M216M327%
Total Cash155M34.6M448%
Total Debt646M76.1M849%
FUNDAMENTALS RATINGS
CRLBF vs GLASF: Fundamental Ratings
CRLBF
GLASF
OUTLOOK RATING
1..100
2024
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
94
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9594
PRICE GROWTH RATING
1..100
3740
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
46n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRLBF's Valuation (76) in the null industry is in the same range as GLASF (94). This means that CRLBF’s stock grew similarly to GLASF’s over the last 12 months.

CRLBF's Profit vs Risk Rating (100) in the null industry is in the same range as GLASF (100). This means that CRLBF’s stock grew similarly to GLASF’s over the last 12 months.

GLASF's SMR Rating (94) in the null industry is in the same range as CRLBF (95). This means that GLASF’s stock grew similarly to CRLBF’s over the last 12 months.

CRLBF's Price Growth Rating (37) in the null industry is in the same range as GLASF (40). This means that CRLBF’s stock grew similarly to GLASF’s over the last 12 months.

CRLBF's P/E Growth Rating (100) in the null industry is in the same range as GLASF (100). This means that CRLBF’s stock grew similarly to GLASF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRLBFGLASF
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
74%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
80%
Momentum
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
71%
MACD
ODDS (%)
N/A
Bullish Trend 3 days ago
65%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
68%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
72%
Advances
ODDS (%)
Bullish Trend 5 days ago
83%
Bullish Trend 4 days ago
78%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 18 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
68%
Aroon
ODDS (%)
Bullish Trend 3 days ago
83%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CRLBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GLASF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TGRFX7.270.01
+0.14%
Transamerica International Focus R6
HGIFX57.67-0.24
-0.41%
Hartford Core Equity F
PCVCX9.52-0.06
-0.63%
Virtus NFJ Small-Cap Value C
PKSAX52.52-0.61
-1.15%
Virtus KAR Small-Cap Core A
LZFOX8.88-0.47
-5.03%
Lazard Equity Franchise Open Shares

CRLBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRLBF has been closely correlated with TCNNF. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRLBF jumps, then TCNNF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRLBF
1D Price
Change %
CRLBF100%
-1.25%
TCNNF - CRLBF
75%
Closely correlated
-7.35%
TSNDF - CRLBF
75%
Closely correlated
+1.10%
CURLF - CRLBF
73%
Closely correlated
-9.48%
VRNOF - CRLBF
72%
Closely correlated
-19.33%
GTBIF - CRLBF
71%
Closely correlated
-12.40%
More

GLASF and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLASF has been loosely correlated with TSNDF. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if GLASF jumps, then TSNDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLASF
1D Price
Change %
GLASF100%
-6.40%
TSNDF - GLASF
62%
Loosely correlated
+1.10%
GTBIF - GLASF
62%
Loosely correlated
-12.40%
TCNNF - GLASF
58%
Loosely correlated
-7.35%
VRNOF - GLASF
58%
Loosely correlated
-19.33%
CRLBF - GLASF
57%
Loosely correlated
-1.25%
More